The pharmacotherapy of treatment-resistant anxiety disorders in adults in the setting of cognitive-behavioral therapy

Treatment Resistant Anxiety Disorders: Resolving Impasses to Symptom Remission

Volumn , Issue , 2009, Pages 323-346

  Kolivakis, Theodore T ^a   Margolese, Howard C ^a   Ducharme, Simon ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84909215484     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9780203893869     Document Type: Chapter

References (91)

1. Alonso, P., Menchon, J.M., Pifarre, J., Mataix-Cols, D., Torres, L., Salgado, P. et al. (2001). Long-term follow-up and predictors of clinical outcome in obsessive- compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. Journal of Clinical Psychiatry, 62(7), 535-540.
2. American Psychiatric Association. (1998). Practice guideline for the treatment of patients with panic disorder. American Journal of Psychiatry, 155(5 Suppl.), 1-34.
3. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text revision). Arlington, VA: American Psychiatric Association.
4. Andrews, G., Henderson, S., & Hall, W. (2001). Prevalence, comorbidity, disability and service utilisation: Overview of the Australian National Mental Health Survey. British Journal of Psychiatry, 178, 145-153.
5. Antony, M.M., & Barlow, D.H. (2002). Specific phobias. In D.H. Barlow (Ed.), Anxiety and its disorders: The nature and treatment of anxiety and panic. New York: Guilford Press.
6. Audet, A.M., Greenfield, S., & Field, M. (1990). Medical practice guidelines: current activities and future directions. Annals of Internal Medicine, 113(9), 709-714.
7. Baldwin, D.S., Anderson, I.M., Nutt, D.J., Bandelow, B., Bond, A., Davidson, J.R. et al. (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 19(6), 567-596.
8. Ballenger, J.C. (1999). Current treatments of the anxiety disorders in adults. Biological Psychiatry, 46(11), 1579-1594.
9. Ballenger, J.C. (2001). Treatment of anxiety disorders to remission. Journal of Clinical Psychiatry, 62(Suppl. 12), 5-9.
10. Bandelow, B., & Ruther, E. (2004). Treatment-resistant panic disorder. CNS Spectrums, 9(10), 725-739.
11. Bandelow, B., Seidler-Brandler, U., Becker, A., Wedekind, D., & Ruther, E. (2007). Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World Journal of Biological Psychiatry, 8(3), 175-187.
12. Bandelow, B., Zohar, J., Hollander, E., Kasper, S., & Moller, H.J. (2002). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World Journal of Biological Psychiatry, 3(4), 171-199.
13. Barlow, D.H., Gorman, J.M., Shear, M.K., & Woods, S.W. (2000). Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. Journal of the American Medical Association, 283(19), 2529-2536.
14. Barnett, S.D., Kramer, M.L., Casat, C.D., Connor, K.M., & Davidson, J.R. (2002). Efficacy of olanzapine in social anxiety disorder: a pilot study. Journal of Psychopharmacology, 16(4), 365-368.
15. Bebbington, P.E., Brugha, T.S., Meltzer, H., Jenkins, R., Ceresa, C., Farrell, M. et al. (2000). Neurotic disorders and the receipt of psychiatric treatment. Psycholological Medicine, 30(6), 1369-1376.
16. Bebbington, P.E., Meltzer, H., Brugha, T.S., Farrell, M., Jenkins, R., Ceresa, C. et al. (2000). Unequal access and unmet need: neurotic disorders and the use of primary care services. Psycholological Medicine, 30(6), 1359-1367.
17. Benjamin, J., Ben-Zion, I.Z., Karbofsky, E., & Dannon, P. (2000). Doubleblind placebo-controlled pilot study of paroxetine for specific phobia. Psychopharmacology (Berlin), 149(2), 194-196.
18. Bhanji, N.H., Chouinard, G., Kolivakis, T., & Margolese, H.C. (2006). Persistent Tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena. Canadian Journal of Clinical Pharmacology, 13(1), e69-74.
19. Blake, D.D., Weathers, F.W., Nagy, L.M., Kaloupek, D.G., Gusman, F.D., Charney, D.S. et al. (1995). The development of a clinician administered PTSD scale. Journal of Traumatic Stress, 8, 75-90.
20. Blier, P., & de Montigny, C. (1992). Lack of efficacy of lithium augmentation in obsessive-compulsive disorder: The perspective of different regional effects of lithium on serotonin release in the central nervous system. Journal of Clinical Psychopharmacology, 12(1), 65-66.
21. Boyer, E.W., & Shannon, M. (2005). The serotonin syndrome. New England Journal of Medicine, 352(11), 1112-1120.
22. Brawman -Mintzer, O., Knapp, R.G., & Nietert, P.J. (2005). Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 66(10), 1321-1325.
23. Brown, T.A., & Barlow, D.H. (1995). Long-term outcome in cognitive-behavioral treatment of panic disorder: clinical predictors and alternative strategies for assessment. Journal of Consulting and Clinical Psychology, 63(5), 754-765.
24. Bystritsky, A. (2006). Treatment-resistant anxiety disorders. Molecular Psychiatry, 11(9), 805-814.
25. Calvocoressi, L., McDougle, C.I., Wasylink, S., Goodman, W.K., Trufan, S.J., & Price, L.H. (1993). Inpatient treatment of patients with severe obsessive- compulsive disorder. Hospital & Community Psychiatry, 44(12), 1150-1154.
26. Canadian Psychiatric Association. (2006). Clinical practice guidelines: Management of anxiety disorders. Canadian Journal of Psychiatry, 51(8, Suppl. 2), 9S-91S.
27. Chilvers, C., Dewey, M., Fielding, K., Gretton, V., Miller, P., Palmer, B. et al. (2001). Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms. British Medical Journal, 322(7289), 772-775.
28. Cottraux, J., Note, I.D., Cungi, C., Legeron, P., Heim, F., Chneiweiss, L. et al. (1995). A controlled study of cognitive-behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. British Journal of Psychiatry, 167(5), 635-641.
29. Coupland, N.J., Bell, C.J., & Potokar, J.P. (1996). Serotonin reuptake inhibitor withdrawal. Journal of Clinical Psychopharmacology, 16(5), 356-362.
30. Crossley, N.A., & Bauer, M. (2007). Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. Journal of Clinical Psychiatry, 68(6), 935-940.
31. Endicott, J., Nee, J., Harrison, W., & Blumenthal, R. (1993). Quality of life enjoyment and satisfaction questionnaire: A new measure. Psychopharmacology Bulletin, 29(2), 321-326.
32. Foa, E.B., Franklin, M.E., & Moser, J. (2002). Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? Biological Psychiatry, 52(10), 987-997.
33. Foa, E.B., Liebowitz, M.R., Kozak, M.J., Davies, S., Campeas, R., Franklin, M.E. et al. (2005). Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive- compulsive disorder. American Journal of Psychiatry, 162(1), 151-161.
34. Goodman, W.K., Price, L.H., Rasmussen, S.A., Mazure, C., Delgado, P., Heninger, G.R. et al. (1989a). The Yale-Brown Obsessive Compulsive Scale. II. Validity. Archives of General Psychiatry, 46(11), 1012-1016.
35. Goodman, W.K., Price, L.H., Rasmussen, S.A., Mazure, C., Fleischmann, R.L., Hill, C.L. et al. (1989b). The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Archives of General Psychiatry, 46(11), 1006-1011.
36. Gosselin, P., Ladouceur, R., Morin, C.M., Dugas, M.J., & Baillargeon, L. (2006). Benzodiazepine discontinuation among adults with GAD: A randomized trial of cognitive-behavioral therapy. Journal of Consulting and Clinical Psychology, 74(5), 908-919.
37. Greenberg, P.E., Sisitsky, T., Kessler, R.C., Finkelstein, S.N., Berndt, E.R., Davidson, J.R. et al. (1999). The economic burden of anxiety disorders in the 1990s. Journal of Clinical Psychiatry, 60(7), 427-435.
38. Guastella, A.J., Richardson, R., Lovibond, P.F., Rapee, R.M., Gaston, J.E., Mitchell, P. et al. (2008). A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biological Psychiatry, 63(6), 544-549.
39. Heldt, E., Gus Manfro, G., Kipper, L., Blaya, C., Isolan, L., & Otto, M.W. (2006). One-year follow-up of pharmacotherapy-resistant patients with panic disorder treated with cognitive-behavior therapy: Outcome and predictors of remission. Behavior Research and Therapy, 44(5), 657-665.
40. Heresco-Levy, U., Kremer, I., Javitt, D.C., Goichman, R., Reshef, A., Blanaru, M. et al. (2002). Pilot-controlled trial of d-cycloserine for the treatment of post-traumatic stress disorder. International Journal of Neuropsychopharmacology, 5(4), 301-307.
41. Hirschmann, S., Dannon, P.N., Iancu, I., Dolberg, O.T., Zohar, J., & Grunhaus, L. (2000). Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology, 20(5), 556-559.
42. Hoffart, A., Due-Madsen, J., Lande, B., Gude, T., Bille, H., & Torgersen, S. (1993). Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. Journal of Clinical Psychiatry, 54(12), 481-487.
43. Hohagen, F., Winkelmann, G., Rasche-Ruchle, H., Hand, I., Konig, A., Munchau, N. et al. (1998). Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo: Results of a multicentre study. British Journal of Psychiatry, 173(Suppl. 35), 71-78.
44. Hollifield, M., Thompson, P.M., Ruiz, J.E., & Uhlenhuth, E.H. (2005). Potential effectiveness and safety of olanzapine in refractory panic disorder. Depression and Anxiety, 21(1), 33-40.
45. Ipser, J.C., Carey, P., Dhansay, Y., Fakier, N., Seedat, S., & Stein, D.J. (2006). Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Systematic Reviews, 4, CD005473.
46. Issakidis, C., Sanderson, K., Corry, J., Andrews, G., & Lapsley, H. (2004). Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders. Psychological Medicine, 34(1), 19-35.
47. Jenkins, R., Bebbington, P., Brugha, T., Farrell, M., Gill, B., Lewis, G. et al. (1997). The national psychiatric morbidity surveys of Great Britain: strategy and methods. Psychological Medicine, 27(4), 765-774.
48. Kopecek, M., Mohr, P., & Novak, T. (2006). Sedative effects of low-dose risperidone in GAD patients and risk of drug interactions. Journal of Clinical Psychiatry, 67(8), 1307-1308; author reply, 1308-1309.
49. Koran, L.M., Hanna, G.L., Hollander, E., Nestadt, G., & Simpson, H.B. (2007). Practice guideline for the treatment of patients with obsessive-compulsive disorder. American Journal of Psychiatry, 164(7 Suppl.), 5-53.
50. Kordon, A., Kahl, K.G., Broocks, A., Voderholzer, U., Rasche-Rauchle, H., & Hohagen, F. (2005). Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up. European Archives of Psychiatry and Clinical Neuroscience, 255(1), 48-50.
51. Leahy, R.L. (2003). Emotional schemas and resistance in cognitive therapy, in R.L. Leahy (Ed.), Roadblocks in cognitive-behavioral therapy: Transforming challenges into opportunities for change, New York: Guilford Press.
52. Liebowitz, M.R. (1998). Anxiety disorders and obsessive compulsive disorder. Neuropsychobiology, 37, 69-71.
53. Lipsman, N., Neimat, J.S., & Lozano, A.M. (2007). Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: The search for a valid target. Neurosurgery, 61(1), 1-11; discussion, 11-13.
54. Londborg, P.D., Hegel, M.T., Goldstein, S., Goldstein, D., Himmelhoch, J.M., Maddock, R. et al. (2001). Sertraline treatment of posttraumatic stress disorder: Results of 24 weeks of open-label continuation treatment. Journal of Clinical Psychiatry, 62(5), 325-331.
55. Looper, K.J. (2007). Potential medical and surgical complications of serotonergic antidepressant medications. Psychosomatics, 48(1), 1-9.
56. Maina, G., Albert, U., Ziero, S., & Bogetto, F. (2003). Antipsychotic augmentation for treatment-resistant obsessive-compulsive disorder: What if antipsychotic is discontinued? International Clinical Psychopharmacology, 18(1), 23-28.
57. Maina, G., Pessina, E., Albert, U., & Bogetto, F. (2008). 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. European Neuropsychopharmacology, 18(5), 364-372.
58. Marks, I.M., Swinson, R.P., Basoglu, M., Kuch, K., Noshirvani, H., O'Sullivan, G. et al. (1993). Alprazolam and exposure alone and combined in panic disorder with agoraphobia: A controlled study in London and Toronto. British Journal of Psychiatry, 162, 776-787.
59. McDougle, C.J., Goodman, W.K., Leckman, J.F., Holzer, J.C., Barr, L.C., McCance-Katz, E. et al. (1993). Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. American Journal of Psychiatry, 150(4), 647-649.
60. McDougle, C.J., Price, L.H., Goodman, W.K., Charney, D.S., & Heninger, G.R. (1991). A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: Lack of efficacy. Journal of Clinical Psychopharmacology, 11(3), 175-184.
61. Mellman, T.A., Miller, A.L., Weissman, E.M., Crismon, M.L., Essock, S.M., & Marder, S.R. (2001). Evidence-based pharmacologic treatment for people with severe mental illness: a focus on guidelines and algorithms. Psychiatric Services, 52(5), 619-625.
62. Mitte, K. (2005a). Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: A comparison with pharmacotherapy. Psychology Bulletin, 131(5), 785-795.
63. Mitte, K. (2005b). A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. Journal of Affective Disorders, 88(1), 27-45.
64. Montgomery, D. (2002). ECNP consensus meeting March 19-22, 2000: Guidelines for investigating efficacy in GAD. European Neuropsychopharmacology, 12(1), 81-87.
65. Montgomery, S., & Bech, P. (2000). ECNP consensus meeting, March 5-6, 1999, Nice: Posttraumatic stress disorder-guidelines for investigating efficacy of pharmacological intervention. ECNP and ECST. European Neuropsychopharmacology, 10(4), 297-303.
66. Montgomery, S.A., Lecrubier, Y., Baldwin, D.S., Kasper, S., Lader, M., Nil, R. et al. (2004). ECNP consensus meeting, March 12-14, 2003: Guidelines for the investigation of efficacy in social anxiety disorder. European Neuropsychopharmacology, 14(5), 425-433.
67. Otto, M.W., Hinton, D., Korbly, N.B., Chea, A., Ba, P., Gershuny, B.S. et al. (2003). Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study of combination treatment with cognitive-behavior therapy vs. sertraline alone. Behavior Research and Therapy, 41(11), 1271-1276.
68. Otto, M.W., Pollack, M.H., Penava, S.J., & Zucker, B.G. (1999). Group cognitive- behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: A clinical case series. Behavior Research and Therapy, 37(8), 763-770.
69. Pae, C.U., Lim, H.K., Peindl, K., Ajwani, N., Serretti, A., Patkar, A.A. et al. (2008). The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials. International Clinical Psychopharmacology, 23(1), 1-8.
70. Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti, D. et al. (2002). Treatment non-response in OCD: Methodological issues and operational definitions. International Journal of Neuropsychopharmacology, 5(2), 181-191.
71. Pickworth, W.B., Sharpe, L.G., Nozaki, M., & Martin, W.R. (1977). Sleep suppression induced by intravenous and intraventricular infusions of methoxamine in the dog. Experimental Neurology, 57(3), 999-1011.
72. Pollack, M.H., Otto, M.W., Roy-Byrne, P.P., Coplan, J.D., Rothbaum, B.O., Simon, N.M. et al. (2008). Novel treatment approaches for refractory anxiety disorders. Depression and Anxiety, 25(6), 467-476.
73. Pollack, M.H., Simon, N.M., Zalta, A.K., Worthington, J.J., Hoge, E.A., Mick, E. et al. (2006). Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: A placebo-controlled study. Biological Psychiatry, 59(3), 211-215.
74. Power, K.G., Simpson, R.J., Swanson, V., Wallace, L.A., Feistner, A. T.C., & Sharp, D. (1990). A controlled comparison of cognitive- behaviour therapy, diazepam, and placebo, alone and in combination, for the treatment of generalised anxiety disorder. Journal of Anxiety Disorders, 4(4), 267-292.
75. Powers, M.B., Smits, J.A., Whitley, D., Bystritsky, A., & Telch, M.J. (2008). The effect of attributional processes concerning medication taking on return of fear. Journal of Consulting and Clinical Psychology, 76(3), 478-490.
76. Raffa, S.D., Stoddard, J.A., White, K.S., Barlow, D.H., Gorman, J.M., Shear, M.K., & Woods, S.W. (2008). Relapse following combined treatment discontinuation in a placebo-controlled trial for panic disorder. Journal of Nervous and Mental Disease, 196(7), 548-555.
77. Raskind, M.A., Peskind, E.R., Kanter, E.D., Petrie, E.C., Radant, A., Thompson, C.E. et al. (2003). Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: A placebo-controlled study. American Journal of Psychiatry, 160(2), 371-373.
78. Ressler, K.J., Rothbaum, B.O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E. et al. (2004). Cognitive enhancers as adjuncts to psychotherapy: Use of d-cycloserine in phobic individuals to facilitate extinction of fear. Archives of General Psychiatry, 61(11), 1136-1144.
79. Rothbaum, B.O., Killeen, T.K., Davidson, J.R., Brady, K.T., Connor, K.M., & Heekin, M.H. (2008). Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. Journal of Clinical Psychiatry, 69(4), 520-525.
80. Sanderson, W.C., DiNardo, P.A., Rapee, R.M., & Barlow, D.H. (1990). Syndrome comorbidity in patients diagnosed with a DSM-III-R anxiety disorder. Journal of Abnormal Psychology, 99(3), 308-312.
81. Siegel, L., Jones, W.C., & Wilson, J.O. (1990). Economic and life consequences experienced by a group of individuals with panic disorder. Journal of Anxiety Disorders, 4, 201-211.
82. Simon, N.M., Connor, K.M., Lang, A.J., Rauch, S., Krulewicz, S., LeBeau, R.T. et al. (2008). Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. Journal of Clinical Psychiatry, 69(3), 400-405.
83. Simpson, H.B., Foa, E.B., Liebowitz, M.R., Ledley, D.R., Huppert, J.D., Cahill, S. et al. (2008). A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. American Journal of Psychiatry, 165(5), 621-630.
84. Simpson, H.B., Huppert, J.D., Petkova, E., Foa, E.B., & Liebowitz, M.R. (2006). Response versus remission in obsessive-compulsive disorder. Journal of Clinical Psychiatry, 67(2), 269-276.
85. Sookman, D., & Pinard, G. (1999). Integrative cognitive therapy for obsessive-compulsive disorder which focuses on multiple schemas. Cognitive and Behavioral Practice, 6(3), 351-361.
86. Stein, M.B., Sareen, J., Hami, S., & Chao, J. (2001). Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. American Journal of Psychiatry, 158(10), 1725-1727.
87. Storch, E.A., Merlo, L.J., Bengtson, M., Murphy, T.K., Lewis, M.H., Yang, M.C. et al. (2007). d-Cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. International Clinical Psychopharmacology, 22(4), 230-237.
88. Ursano, R.J., Bell, C., Eth, S., Friedman, M., Norwood, A., Pfefferbaum, B. et al. (2004). Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. American Journal of Psychiatry, 161(11 Suppl.), 3-31.
89. Vaishnavi, S., Alamy, S., Zhang, W., Connor, K.M., & Davidson, J.R. (2007). Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31(7), 1464-1469.
90. Wilhelm, S., Buhlmann, U., Tolin, D.F., Meunier, S.A., Pearlson, G.D., Reese, H. E. et al. (2008). Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. American Journal of Psychiatry, 165(3), 335-341; quiz, 409.
91. Woodward, S.H., Arsenault, N.J., Murray, C., & Bliwise, D.L. (2000). Laboratory sleep correlates of nightmare complaint in PTSD inpatients. Biological Psychiatry, 48(11), 1081-1087.